Medigene AG (ETR:MDG1 – Get Free Report) fell 8.7% on Wednesday . The company traded as low as €0.17 ($0.19) and last traded at €0.19 ($0.22). 63,357 shares changed hands during trading, a decline of 79% from the average session volume of 306,207 shares. The stock had previously closed at €0.21 ($0.24).
Medigene Price Performance
The business’s 50-day simple moving average is €1.24 and its 200 day simple moving average is €1.41. The company has a market capitalization of $1.45 million, a P/E ratio of -0.32, a P/E/G ratio of 7.12 and a beta of 0.84. The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.95.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Read More
- Five stocks we like better than Medigene
- The 3 Best Fintech Stocks to Buy Now
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- Are Penny Stocks a Good Fit for Your Portfolio?
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- 5 Top Rated Dividend Stocks to Consider
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
